A comparative test of fifteen compounds against all known human rhinovirus serotypes as a basis for a more rational screening program.
A systematic evaluation of 15 rhinovirus capsid-binding agents against all 100 serotyped human rhinoviruses revealed the existence of two virus groups, based upon differential susceptibility to antiviral compounds. Elongated and short-chained compounds preferentially inhibited groups A and B. The positions of the rhinoviruses within a map derived from a multivariate analysis allow for the selection of a panel of 17 rhinoviruses, for which the median antiviral inhibitory value against them will accurately predict the median value against 100 serotypes. This rationalizes the search for broad-spectrum capsid-binding antirhinovirus drugs, or combinations of drugs with complementary spectra that may be necessary to effectively inhibit both type A and type B viruses.
Andries
K
K
Janssen Research Foundation, Beerse, Belgium.
Dewindt
B
B
Snoeks
J
J
Willebrords
R
R
Stokbroekx
R
R
Lewi
P J
PJ
D000998:Antiviral Agents / Q000378:metabolism / Q000494:pharmacology*; D002213:Capsid / Q000378:metabolism; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D007555:Isoxazoles / Q000378:metabolism / Q000494:pharmacology; D008954:Models, Biological; D012229:Rhinovirus / Q000145:classification / Q000187:drug effects*; D013329:Structure-Activity Relationship
D000998:Antiviral Agents; D007555:Isoxazoles; C045978:disoxaril